Aignostics, a global artificial intelligence (AI) company that turns complex multi-modal pathology data into transformative insights, has raised $34 million in Series B financing. The oversubscribed funding round was led by ATHOS, with investments from Mayo Clinic and growth financing from HTGF, alongside support from existing investors.
As precision medicine becomes more nuanced and complex, biopharmaceutical companies are increasingly turning to AI to enhance the utility, performance, and scalability of computational pathology analyses for drug development and diagnostics. In parallel, machine learning technologies are rapidly evolving, producing AI models with record accuracy and robustness, opening new avenues for biopharmaceutical research and diagnostics.
The new funding will strengthen Aignostics’ offerings for target ID, translational research, and companion diagnostics (CDx), and support several strategic initiatives.
Established in 2018 in the Digital Health Accelerator program of Charité BIH Innovation and funded by the Berlin Institute of Health at Charité (BIH), Aignostics is a spin-off from Charité – Universitätsmedizin Berlin and has operations in Berlin and New York. Ascenion holds equity in Aignostics. Revenues Ascenion may receive from a potential future exit will largely be distributed to the LifeScience Foundation, which in turn will make them available to its endowing institutes as research grants.
For more information, see Aignostics’ press release
Ascenion’s portfolio company Aignostics secures $34 million Series B financing
The additional funding will be used to build new product offerings for biopharmaceutical clients, fuel growth within the United States (US), and develop a leading foundation model for pathology in collaboration with Mayo Clinic.
